I
Iambic Therapeutics
AI-driven chemistry for medicine
About Iambic Therapeutics
Iambic Therapeutics is a clinical-stage biotechnology company that leverages its proprietary AI-driven discovery platform to develop novel therapeutics, with a primary focus on oncology and neurological diseases. The company's platform utilizes advanced AI models and automated experimental approaches to accelerate the identification and development of drug candidates. This technology enables a significant reduction in the time and data required for predicting molecular properties, thereby streamlining the drug discovery process. The business model encompasses both the independent development of a proprietary pipeline of drug candidates and strategic partnerships with other pharmaceutical companies. These collaborations leverage Iambic's AI capabilities for joint drug discovery efforts. The company generates revenue through the advancement of its internal pipeline and through milestones and royalties from its partnerships. Iambic Therapeutics serves the pharmaceutical and biotechnology markets by providing a new avenue for the discovery of treatments for complex diseases.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- San Diego, United States
- Employees
- 159
- Open positions
- None listed
- Dealroom signal
- 94.4/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Spinout, Tech for Biotech and Pharma, Generative AI, UKSU, UKSU2010, AI Drug Discovery, genAI Applications
- Business model
- SaaS
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Nov 2025 | $100M | $400M | Qatar Investment Authority · Alexandria Venture Investments · Alumni Ventures · Terra Magnum Capital Partners | ↗ |
| SERIES BOther financing | Jun 2024 | $50M | $500M | Abingworth · Qatar Investment Authority · Illumina Ventures · Exor Ventures | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Iambic Therapeutics is 10K monthly website visits, down 28.6% over the last three months. Iambic Therapeutics's team grew 31.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A14 investors entered at this stage
Coatue Management
Catalio Capital Management
Sequoia
OrbiMed
Nexus Ventures
Freeflow Ventures
Abingworth
Ascenta Capital
Nvidia
Illumina Ventures
Gradiant
Exor Ventures
Mubadala Capital
Qatar Investment Authority
Series B and later9 investors entered at this stage
Alexandria Venture Investments
Alumni Ventures- TPTerra Magnum Capital Partners
Regeneron Ventures- EBEverbright Biofund
Pegasus Tech Ventures
Tao Capital Partners
Wilson Sonsini
ARK Invest
Other known investors2 additional known investors
Imperial College London
University of Bristol
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Iambic Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Iambic Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.